Immunological checkpoint blockade therapies benefit a limited population of cancer patients. We have previously shown that vaccine immunotherapy with Toll-like receptor (TLR)3-adjuvant and tumor antigen overcomes anti-programmed death ligand-1 (PD-L1) resistance in mouse tumor models. In the present study, 4 different ovalbumin 
that harnesses the immune system to attack malignant cells. Since then, rapid exploration into this field has been conducted using new technologies that allow the detection of tumorigenic mutations, TAA and tumor-specific CTL. In fact, immunological checkpoint blockade therapies have led to complete remission in some progressive cancers when appropriate antigens are expressed. [1] [2] [3] [4] [5] [6] Responses to PD-1/PD-L1 blockade therapies are associated with pre-existing tumor-reactive CD8 + T cells and non-synonymous mutational burden in tumors. 1, 4, 5, 7 As the generation of tumor-specific CTL and the number of cancer neoantigens differ between tumor types, and as T-cell infiltration is regulated by the tumor microenvironment, [8] [9] [10] only approximately 20%-30% of solid tumors in patients have responded to PD-1/PD-L1-targeted therapies. 11, 12 PD-L1 levels in both tumor and host cells affect the efficacy of PD-1/ PD-L1 blockade therapy. [13] [14] [15] [16] [17] Furthermore, even if tumor-specific CTL are generated, they often become exhausted and acquire epigenetic stability that limits the durability of reinvigoration by PD-1 blockade during continuous antigen stimulation. 18 In PD-1 blockade-unresponsive tumors, fewer tumor-specific CTL appear to be induced by intrinsic factors. We have previously shown that forced tumor-specific CTL induction by vaccine immunotherapy TAA and the TLR3-specific adjuvant, ARNAX, efficiently eradicates tumors in PD-1/PD-L1 blockade-unresponsive mouse tumor models. 19, 20 Combined ARNAX and TAA treatment induces tumor-specific CTL, facilitates T-cell infiltration into tumors, modulates the tumor microenvironment to establish Th1-type anti-tumor immunity, and leads to tumor regression without inflammation. However, the therapeutic efficacy of the ARNAX vaccine depended on the tumor type. 20 In the present study, we analyzed the tumor microenvironment in ARNAX-sensitive and -resistant mouse tumor models to uncover factors that influence the efficacy of TLR3 adjuvant therapy. Our data show that tumor-specific memory CTL are generated in ARNAX-sensitive tumors, and that they inhibit the tumor growth of reimplanted tumors.
| MATERIALS AND METHODS

| Mice
WT C57BL/6J mice were purchased from CLEA Japan (Tokyo, Japan). Ticam1 À/À mice were bred in our laboratory. 21 Ifnar À/À mice were kindly provided by Dr T. Taniguchi (Tokyo University, Tokyo, Japan). Tlr3 À/À and Myd88 À/À were kindly provided by Dr S. Akira (Osaka University, Osaka, Japan). All mice were back-crossed >8
times to C57BL/6 background and maintained under specific pathogen-free conditions in the animal faculty of the Hokkaido University Graduate School of Medicine. All animal research protocols for this work were reviewed and approved by the Animal Safety Center (#17-0096) of Hokkaido University, Japan. 
| Cells
| Reagents and antibodies
ARNAX having 120 and 140 bp dsRNA (named ARNAX-120 and ARNAX-140, respectively) were synthesized as described 19 by GeneDesign, Inc. (Osaka, Japan). TLR3 agonistic activity of ARNAX-120
was comparable to that of ARNAX-140 ( Figure S1 ). Poly(I:C) (27-4732-01) was purchased from GE Healthcare Life Sciences; recombinant mouse IFN-c (575302) was from BioLegend (San Diego, CA, USA); EndoGradeâ Ovalbumin (OVA) (321001) was from Hyglos; OVA (H2Kb-SL8) tetramer (TS-5001-P) and OVA 257-264 peptide (SIINFEKL: SL8) (TS-5001-P) were from MBL. Anti-PD-L1 antibody (Ab) (clone: 10F.9G2, catalog number: BE0101) and rat IgG2b isotype control Ab (LTF-2, BE0090) were purchased from Bio X Cell.
Abs used for flow cytometry analysis are listed in Table S1 . Figure 1D , right panel). 20 These results suggest that the efficacy of the ARNAX vaccine depends on tumor type.
| Tumor challenge and ARNAX therapy
To elucidate the factors that influence responsiveness to ARNAX therapy, we assessed PD-L1 and MHC class I levels in tumor cells, as these proteins affect CTL-dependent anti-tumor response. 25 
anti-PD-L1 Ab, and complete tumor regression was observed in 40% of mice. Addition of the anti-PD-L1 Ab failed to produce additional improvements ( Figure 5A ). There was no significant dif- 
| DISCUSSION
The goal of the present study was to unveil factors that affect vaccine therapy for cancer unresponsive to PD-1/PD-L1 blockade therapy. We have previously shown that ARNAX therapy relieves resistance to PD-L1 blockade and evokes anti-tumor immunity without systemic inflammatory cytokinemia in tumor-bearing mouse models. 20 Herein, we showed that ARNAX therapy induced com- F i r s t -i m p l a n t a t i o n R e -i m p l a n t a t i o n F i r s t -i m p l a n t a t i o n R e -i m p l a n t a t i o n (C) can induce both OVA-specific CD4 + and CD8 + T cells, the outcome of which is quite different from the vaccine using SL8 killer peptide. 
